All articles tagged with #fusobacterium nucleatum
Research suggests that high levels of the oral bacterium Fusobacterium nucleatum may be linked to increased disability in multiple sclerosis patients, indicating a possible MS-specific oral–brain inflammatory pathway and highlighting the importance of oral health in disease progression.
Fusobacterium nucleatum, an oral bacterium, has been linked to the development and progression of colorectal cancer by binding to cancer cells and activating growth factors that promote cancer proliferation and metastasis. Maintaining good oral hygiene is crucial in managing this bacterium, reducing the risk of gum disease and its potential systemic health impact. Scientists are exploring ways to develop screening tools and therapies to neutralize the threat posed by Fusobacterium nucleatum, emphasizing the importance of oral health in preventing inflammation and keeping harmful oral bacteria at bay.
Research shows that a specific subtype of the oral bacterium Fusobacterium nucleatum, known as Fna C2, is linked to the growth of colon tumors and is more prevalent in colon cancer patients. This finding could lead to new insights into fighting colon cancer and the development of targeted therapies. The discovery of this bacterial subtype's association with colorectal cancer is crucial for the development of effective preventive and treatment methods.
A study has found that a specific subtype of the oral bacterium Fusobacterium nucleatum, known as Fna C2, can travel from the mouth to colon tumors and accelerate their growth. This discovery could lead to new insights into combating colon cancer, which claims over 52,000 lives in the U.S. annually. The presence of Fna C2 was linked to poorer prognosis in colorectal cancer patients, and researchers suggest that targeting this bacterial subgroup could improve treatment and prevention methods, potentially through microbe-based cellular therapies.
A study published in Nature found that a type of bacteria, Fusobacterium nucleatum, typically found in the mouth, was discovered in 50% of colorectal tumors and appears to shield tumor cells from cancer-fighting drugs. This discovery could lead to new treatments and screening methods for colorectal cancer, which is on the rise, particularly among younger people. The bacteria's stealthy subspecies was found to worsen prognosis and may even cause cancer to form. The findings could lead to targeted therapies, including antibiotics and potentially genetically modifying the bacteria to carry cancer-fighting drugs directly into tumors.
A study reveals that a specific clade within the Fusobacterium nucleatum (Fn) subspecies dominates the colorectal cancer (CRC) niche, with in vitro and in vivo studies demonstrating its high virulence in the context of CRC. Comparative genomics and functional studies show that this clade, known as Fna clade 2 (Fna C2), is significantly associated with the CRC niche and possesses distinct genetic and epigenetic characteristics compared to Fna clade 1 (Fna C1). Fna C2 is enriched in CRC tumors and exhibits differential invasion potential and morphological differences compared to Fna C1, shedding light on its potential role in CRC pathogenicity.